🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interdisciplinary #GUCancerForum 2025: Emerging Data and Advances in Screening. Presentation by Tom Jayram Urology Associates. Written coverage by Julian Chavarriaga University of Toronto > bit.ly/40eji9G

Interdisciplinary #GUCancerForum25: Combination Therapies. Presentation by Peter Carroll, MD UCSFUrology. Written coverage by Julian Chavarriaga University of Toronto on UroToday > bit.ly/44cbRBd

Neoadjuvant management of high-risk #ProstateCancer. Presentation by Robert Reiter, MD, MBA UCLA. Written coverage of the 2025 Interdisciplinary #GUCancerForum by Julian Chavarriaga University of Toronto > bit.ly/4kNVXE5

Interdisciplinary #GUCancerForum 2025: #ArtificialIntelligence in molecular targeted imaging and theranostics. Presentation by Dr. David Albala Crouse Health. Written coverage by Julian Chavarriaga University of Toronto > bit.ly/3HP5354

Interdisciplinary #GUCancerForum 2025: Advances in #Immunotherapy. Presentation by Andy Hahn MD Anderson Cancer Center. Written coverage by Julian Chavarriaga University of Toronto > bit.ly/43SXyTf

Interdisciplinary #GUCancerForum 2025: Impact of molecular targeted imaging on nonmetastatic castration resistant #ProstateCancer. Presentation by Shereif Gamie, MD, PhD UC San Diego. Written coverage by Julian Chavarriaga University of Toronto > bit.ly/3HP7i8k

Interdisciplinary #GUCancerForum 2025: Future directions of #mCRPC. Presentation by Andy Hahn MD Anderson Cancer Center. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3TF59yB

Interdisciplinary #GUCancerForum 2025: Novel agents in #NMIBC. Presentation by Leonard Gomella Thomas Jefferson University. Written coverage by Julian Chavarriaga University of Toronto on UroToday > bit.ly/43UxyXG

Interdisciplinary #GUCancerForum 2025: Clinical trial design for the treatment of #NMIBC. Presented by Bernie Bochner, MD Memorial Sloan Kettering Cancer Center. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3G0sCHy

Interdisciplinary #GUCancerForum 2025: New approaches to neoadjuvant therapy for #UrothelialCarcinoma. Presented by Daniel Petrylak Yale Cancer Center. Written coverage by Zach Klaassen Georgia Cancer Center bit.ly/3HMlijr

Interdisciplinary #GUCancerForum 2025: The role of ctDNA in selecting adjuvant therapy post-cystectomy. Presentation by Gennady Bratslavsky Upstate Medical University. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3ZGbYUc

Interdisciplinary #GUCancerForum 2025: The role of ctDNA in monitoring patients with metastatic disease. Presented by Andy Hahn MD Anderson Cancer Center. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/44hgJ8l

Interdisciplinary #GUCancerForum 2025: What is the optimal sequence of treatment for metastatic #UrothelialCarcinoma? Presentation by Daniel Petrylak Yale Medicine. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4lf01wS

Interdisciplinary #GUCancerForum 2025: Novel agents in metastatic #UrothelialCarcinoma. Presentation by Daniel Petrylak Yale Medicine. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/45AejUy

🚨 #SNMMI25 How about Terbium-161? James Buteau Peter Mac Cancer Centre presents first-in-human data on [¹⁶¹Tb]Tb-PSMA-I&T for #mCRPC: dual-action β + Auger emitter hits both bulky tumors and micrometastases. #VIOLET trial shows 70% PSA50, 40% PSA90, low toxicity, and 11 mo rPFS. 💥 A new

A combination of a CD46-targeted antibody-drug conjugate and a radioimmunotherapy agent for the treatment of #ProstateCancer. Presentation by Anil Bidkar UC San Francisco. #SNMMI25 written coverage by Rashid K. Sayyid USC > bit.ly/4n9aPyJ SNMMI #SNMMI2025

🚨 #SNMMI25 Spotlight: #Astatine211 is heating up in advanced #ProstateCancer therapy! 🧬 Potent α-emitter with a 7.2h half-life 🏥 Outpatient-friendly, low off-target exposure 📊 [211At]PSMA-5 shows high tumor uptake & low kidney toxicity 📷 First-in-human SPECT images confirm

A phase 1 trial of 61Cu-NODAGA-PSMA I&T for patients with #ProstateCancer. Presentation by Gary Ulaner, MD, PhD Hoag. #SNMMI25 written coverage by Rashid K. Sayyid USC > bit.ly/4kY8RPW SNMMI #SNMMI2025

First data of a novel PSMA-targeting radiopharmaceutical compound SMS-5368: Exploratory and phase 1/2 results. Presentation by Paul Hatcher, MD utmedicalcenter. #SNMMI25 written coverage by Rashid K. Sayyid USC > bit.ly/3TNg8WM SNMMI #SNMMI2025

🎯🎯 Don't forget to check out the videos of each GUARD presentation! 👉 excellent panel and discussion! #GUARDSymposium2025 supported by OncoAlert in social networks!! GUARD Consortium UroToday.com @uromigos Eric J. Small, MD, FASCO Enrique Grande Yüksel Ürün Julian Chavarriaga Petros Grivas